Patents Assigned to The United States of America as represented by the Department of Health and Human Services
-
Patent number: 12070495Abstract: Provided herein are methods and compositions for inducing in a subject abroad neutralizing antibody response to human immunodeficiency virus (HIV) infection.Type: GrantFiled: March 13, 2020Date of Patent: August 27, 2024Assignees: ModernaTX, Inc., The United States of America, as represented by the Department of Health and Human ServicesInventors: Paolo Lusso, Peng Zhang, Elisabeth Narayanan, Sayda Mahgoub Elbashir
-
Publication number: 20220241399Abstract: Provided herein are methods and compositions for inducing in a subject abroad neutralizing antibody response to human immunodeficiency virus (HIV) infection.Type: ApplicationFiled: March 13, 2020Publication date: August 4, 2022Applicants: Moderna TX, Inc., The United States of America, as represented by the Department of Health and Human ServicesInventors: Paolo Lusso, Peng Zhang, Elisabeth Narayanan, Sayda Mahgoub Elbashir
-
Publication number: 20200172962Abstract: Methods and compositions are provided for the detection of BlaIMP. The disclosed methods and compositions can detect all known IMP variants in a single, rapid assay.Type: ApplicationFiled: June 13, 2018Publication date: June 4, 2020Applicant: The United States of America as represented by the Department of Health and Human ServicesInventors: Linda Maria Erika KARLSSON, Davina Elaine CAMPBELL
-
Publication number: 20190345205Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.Type: ApplicationFiled: November 15, 2017Publication date: November 14, 2019Applicants: GLAXOSMITHKLINE BIOLOGICALS, S.A., The United States of America, as Represented by the Department of Health and Human ServicesInventors: Kimberly DOWD, Barney S. GRAHAM, Sung-Youl KO, Wing-Pui KONG, John MASCOLA, Theodore PIERSON, Mayuri SHARMA, Dong Yu
-
Patent number: 10017494Abstract: The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.Type: GrantFiled: March 19, 2015Date of Patent: July 10, 2018Assignees: Mycovia Pharmaceuticals, Inc., The United States of America, as represented by the Department of Health and Human ServicesInventors: William J. Hoekstra, Christopher M. Yates, Mark Behnke, Asaf Alimardanov, Scott A. David, Douglas Franklin Fry
-
Patent number: 9598703Abstract: An isolated linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods for producing and purifying this nucleic acid molecule, and use of the same for therapeutic purposes are also provided.Type: GrantFiled: March 12, 2012Date of Patent: March 21, 2017Assignees: ASSOCIATION INSTITUT DE MYOLOGIE; UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTÉ DE LAD RECHERCHE MÉDICALE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTHInventors: Luis Garcia, Cyriaque Beley, Thomas Voit, Robert Michael Kotin, Lina Li
-
Patent number: 9526777Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).Type: GrantFiled: April 15, 2011Date of Patent: December 27, 2016Assignees: The United States of America as Represented by the Department of Health and Human Services, Glaxosmithkline Biologicals SAInventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 9254319Abstract: We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).Type: GrantFiled: December 20, 2013Date of Patent: February 9, 2016Assignees: Emory University, The United States of America as represented by The Department of Health and Human ServicesInventors: Harriet Robinson, James Smith, Rama Amara, Bernard Moss, Salvatore T. Butera, Dennis Ellenberger
-
Publication number: 20150004132Abstract: We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).Type: ApplicationFiled: December 20, 2013Publication date: January 1, 2015Applicants: EMORY UNIVERSITY, Centers for Disease Control and Prevention, The United States of America as Represented by the Department of Health and Human ServicesInventors: Harriet Robinson, James Smith, Ram Amara, Bernard Moss, Salvatore T. Butera, Dennis Ellenberger
-
Patent number: 8916172Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.Type: GrantFiled: January 10, 2011Date of Patent: December 23, 2014Assignees: Emory University, National Institute of Allergy and Infectious Diseases (NIAID), The United States of America, as represented by the Department of Health and Human ServicesInventors: Bernard Moss, Linda Wyatt, Patricia Earl, Harriet L. Robinson
-
Patent number: 8829022Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.Type: GrantFiled: October 11, 2011Date of Patent: September 9, 2014Assignees: Purdue Research Foundation, The United States of America as represented by the Department of Health and Human ServicesInventors: Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves G. Pommier, Keli K. Agama, Smitha Antony
-
Patent number: 8628782Abstract: Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions.Type: GrantFiled: February 26, 2010Date of Patent: January 14, 2014Assignee: The United States of America, as Represented by the Department of Health and Human ServicesInventor: Ira Berkower
-
Patent number: 8615291Abstract: Method, system, and computer program method for detecting pathological fluctuations of physiological signals to diagnose human illness. The method comprises performing a sliding window analysis to find sequences in physiological signal data that match amplitude- and duration-adjusted versions of a template function to within a specified tolerance.Type: GrantFiled: March 15, 2010Date of Patent: December 24, 2013Assignees: National Institutes of Health (NIH), The United States of America as Represented by the Department of Health and Human ServicesInventors: Randall Moorman, Douglas E. Lake, Abigail Flower, John B. Delos
-
Patent number: 8538507Abstract: Balloon probes, adapted for use in endoscopy and other medical procedures, are useful to obtain spectroscopic information reflected or emitted from a tissue of interest in the infrared spectral region. The information collected by the probe is useful in the diagnosis and treatment of disease. The invention also relates to methods utilizing these probes to analyze a surface of interest, in a minimally invasive manner, in connection with the diagnosis and treatment of disease.Type: GrantFiled: August 31, 2011Date of Patent: September 17, 2013Assignees: Hypermed Imaging, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Jenny E. Freeman, Charles R. Lambert, Michael J. Hopmeier, Edgar N. Lewis
-
Publication number: 20130073011Abstract: A method of treating spinal cord injury (SCI) includes transcutaneously irradiating at least a portion of a spinal environment of the patient with light having a power density of at least about 0.01 mW/cm2 at the portion of the spinal environment.Type: ApplicationFiled: November 7, 2012Publication date: March 21, 2013Applicants: Henry M. Jackson Foundation for Advancement of Military Medicine, The United State of America as represented by the Department of Health and Human ServicesInventors: The United State of America as represented by th, Henry M. Jackson Foundation for Advancement of
-
Publication number: 20130035363Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.Type: ApplicationFiled: October 10, 2012Publication date: February 7, 2013Applicants: The United States of America as represented by the Department of Health & Human Services, P2D INC.Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
-
Patent number: 8361710Abstract: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents.Type: GrantFiled: March 30, 2011Date of Patent: January 29, 2013Assignees: The Ohio State University Research Foundation, The United States of America as represented by the Department of Health and Human ServicesInventors: Carlo M. Croce, Nozomu Yanaihara, Curtis C. Harris
-
Patent number: 8338104Abstract: The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.Type: GrantFiled: November 15, 2011Date of Patent: December 25, 2012Assignees: The Ohio State University Research Foundation, The United States of America, as represented by the Department of Health and Human Services, National Institute of Health, Office of Technology TransferInventors: Carlo M. Croce, Curtis C. Harris, Aaron J. Schetter
-
Patent number: 8328857Abstract: A method of treating spinal cord injury (SCI) includes transcutaneously irradiating at least a portion of a spinal environment of the patient with light having a power density of at least about 0.01 mW/cm2 at the portion of the spinal environment.Type: GrantFiled: February 25, 2010Date of Patent: December 11, 2012Assignees: The United States of America as represented by the Department of Health and Human Services, Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Juanita J. Anders, Ilko K. Ilev, Ronald W. Waynant, Kimberly R. Byrnes
-
Patent number: 8288530Abstract: Disclosed are methods of preparing a macromolecular conjugated ligand and a metal complex thereof. The metal complex is targeted for use as a contrast agent, for example, in MRI. The method of preparing a macromolecular conjugated ligand comprises: (a) providing a compound of formula (I) wherein R, A, and Pg are as defined herein, (b) reacting the compound of formula (I) with a macromolecular compound (e.g., dendrimer) in an organic solvent medium which is substantially free of water to obtain a macromolecular conjugated compound, and (c) removing the carboxyl-protecting groups to obtain a carboxyl-deprotected macromolecular conjugated compound. The metal complex can be prepared by reacting the carboxyl-deprotected macromolecular conjugated compound with an ion (e.g., Gd(III)). Also disclosed are two carboxyl-protected 1B4M-DTPA intermediate compounds.Type: GrantFiled: November 6, 2007Date of Patent: October 16, 2012Assignee: The United States of America, as represented by the Department of Health and Human ServicesInventors: Martin W. Brechbiel, Heng Xu